Alys Pharmaceuticals, founded in 2024, is establishing itself as an innovation leader in the field of immuno-dermatology. The company emerged from the union of six Medixci asset-centric companies, including Aldena Therapeutics, Graegis Pharmaceuticals, Granular Therapeutics, Klirna Biotech, Nira Biosciences, and Vimela Therapeutics.
The venture has set its sights on transforming treatment paradigms for several dermatology indications that hold significant prevalence and present major unmet medical needs. By leveraging strategic collaborations with leading research institutions, Alys aims to not only redefine but also lead the landscape of dermatological treatments through its innovative programs and platforms.
In its efforts to propel growth and innovation, Alys Pharmaceuticals secured a Seed Round investment of $100.00M from Medicxi on 12 February 2024. For investors, this substantial backing at such an early stage underscores Alys's potential to become a key player in biotechnology and the broader healthcare industry.
